RXRX
Price
$7.52
Change
+$0.03 (+0.40%)
Updated
Jan 23, 04:59 PM (EDT)
Capitalization
2.94B
40 days until earnings call
XERS
Price
$3.41
Change
+$0.12 (+3.65%)
Updated
Jan 23, 04:59 PM (EDT)
Capitalization
508.37M
41 days until earnings call
Ad is loading...

RXRX vs XERS

Header iconRXRX vs XERS Comparison
Open Charts RXRX vs XERSBanner chart's image
Recursion Pharmaceuticals
Price$7.52
Change+$0.03 (+0.40%)
Volume$134.87K
Capitalization2.94B
Xeris Biopharma Holdings
Price$3.41
Change+$0.12 (+3.65%)
Volume$67.84K
Capitalization508.37M
RXRX vs XERS Comparison Chart
Loading...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RXRX vs. XERS commentary
Jan 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RXRX is a Hold and XERS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 24, 2025
Stock price -- (RXRX: $7.49 vs. XERS: $3.29)
Brand notoriety: RXRX and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RXRX: 228% vs. XERS: 48%
Market capitalization -- RXRX: $2.94B vs. XERS: $508.37M
RXRX [@Biotechnology] is valued at $2.94B. XERS’s [@Biotechnology] market capitalization is $508.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $360.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RXRX’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • RXRX’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, XERS is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RXRX’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 1 bullish TA indicator(s).

  • RXRX’s TA Score: 4 bullish, 2 bearish.
  • XERS’s TA Score: 1 bullish, 5 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than XERS.

Price Growth

RXRX (@Biotechnology) experienced а +16.67% price change this week, while XERS (@Biotechnology) price change was +1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.92%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was -1.05%.

Reported Earning Dates

RXRX is expected to report earnings on May 07, 2025.

XERS is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+3.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.94B) has a higher market cap than XERS($508M). RXRX YTD gains are higher at: 10.799 vs. XERS (-2.950). XERS has higher annual earnings (EBITDA): -23.07M vs. RXRX (-350.86M). RXRX has more cash in the bank: 428M vs. XERS (69.4M). RXRX has less debt than XERS: RXRX (90.6M) vs XERS (271M). XERS has higher revenues than RXRX: XERS (187M) vs RXRX (64.6M).
RXRXXERSRXRX / XERS
Capitalization2.94B508M579%
EBITDA-350.86M-23.07M1,521%
Gain YTD10.799-2.950-366%
P/E RatioN/AN/A-
Revenue64.6M187M35%
Total Cash428M69.4M617%
Total Debt90.6M271M33%
FUNDAMENTALS RATINGS
XERS: Fundamental Ratings
XERS
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RXRXXERS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 16 days ago
82%
Momentum
ODDS (%)
Bullish Trend 16 days ago
85%
Bearish Trend 16 days ago
85%
MACD
ODDS (%)
Bullish Trend 16 days ago
81%
Bearish Trend 16 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 16 days ago
81%
Bearish Trend 16 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 16 days ago
84%
Bearish Trend 16 days ago
86%
Advances
ODDS (%)
Bullish Trend 18 days ago
84%
Bullish Trend 21 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
89%
Bearish Trend 17 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 16 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ECERX20.260.22
+1.10%
Eaton Vance Stock C
DODEX8.790.03
+0.34%
Dodge & Cox Emerging Markets Stock
BEXFX15.06-0.04
-0.26%
Baron Emerging Markets Retail
RIRAX70.59-0.29
-0.41%
American Funds Capital Income Bldr R1
EPLKX20.82-0.11
-0.53%
NYLI Epoch U.S. Equity Yield Class C

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+8.87%
CRSP - RXRX
64%
Loosely correlated
+6.48%
BEAM - RXRX
59%
Loosely correlated
+7.58%
PRME - RXRX
55%
Loosely correlated
+9.28%
NTLA - RXRX
54%
Loosely correlated
+10.76%
GLUE - RXRX
50%
Loosely correlated
-2.81%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-1.50%
TRDA - XERS
45%
Loosely correlated
-3.98%
SCPH - XERS
44%
Loosely correlated
-0.93%
RXRX - XERS
43%
Loosely correlated
+8.87%
FHTX - XERS
42%
Loosely correlated
-0.91%
BEAM - XERS
41%
Loosely correlated
+7.58%
More